Increase in the Serum Parathyroid Hormone Level During a Bisphosphonate Drug Holiday
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
After discontinuation of bisphosphonate therapy, an antiresorptive effect and antifrac-ture protection persist for an undefined period. Patients are encouraged to continue cal-cium and vitamin D supplementation, during a bisphosphonate drug holiday. However,assessment of adequate calcium intake during the bisphosphonate drug holiday is diffi-cult. Therefore, we measured the serum intact parathyroid hormone (PTH) level as a sur-rogate marker. A premenopausal woman discontinued bisphosphonate therapy, after7.5 years of treatment. Two months later, blood calcium and phosphorus levels werenormal, serum 25-hydroxyvitamin D level was 31.3 ng/mL, but serum PTH level had in-creased to 94.9 pg/mL. The elemental calcium supplement dose was increased to 600mg/day, with no change in the cholecalciferol dose (400 IU). Her serum PTH levels de-creased to 49.1 after 4 months and 32.9 pg/mL after 5 months. The serum PTH level maybe helpful in assessing adequate calcium intake during a bisphosphonate drug holiday.
Abstract
After discontinuation of bisphosphonate therapy, an antiresorptive effect and antifrac-ture protection persist for an undefined period. Patients are encouraged to continue cal-cium and vitamin D supplementation, during a bisphosphonate drug holiday. However,assessment of adequate calcium intake during the bisphosphonate drug holiday is diffi-cult. Therefore, we measured the serum intact parathyroid hormone (PTH) level as a sur-rogate marker. A premenopausal woman discontinued bisphosphonate therapy, after7.5 years of treatment. Two months later, blood calcium and phosphorus levels werenormal, serum 25-hydroxyvitamin D level was 31.3 ng/mL, but serum PTH level had in-creased to 94.9 pg/mL. The elemental calcium supplement dose was increased to 600mg/day, with no change in the cholecalciferol dose (400 IU). Her serum PTH levels de-creased to 49.1 after 4 months and 32.9 pg/mL after 5 months. The serum PTH level maybe helpful in assessing adequate calcium intake during a bisphosphonate drug holiday.
참고문헌 (28)
- Kleerekoper M, "Primer on the metabolic bone diseases and disorders of mineral metabolism", pp.345~347 (2013), Wiley-Blackwell
- McClung M, "Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday", Am J Med, 126, pp.130~120 (2013)
- MacLean C, "Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis", Ann Intern Med, 148, pp.197~213 (2008)
- Russell RG, "Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy", Osteoporos Int, 19, pp.733~759 (2008)
- Khosla S, "Benefits and risks of bisphosphonate therapy for osteoporosis", J Clin Endocrinol Metab, 97, pp.2272~2282 (2012)
- Diab DL, "Bisphosphonates in the treatment of osteoporosis", Endocrinol Metab Clin North Am, 41, pp.487~506 (2012)
- Bonnick SL, "Going on a drug holiday?", J Clin Densitom, 14, pp.377~383 (2011)
- Ott SM, "What is the optimal duration of bisphosphonate therapy?", Cleve Clin J Med, 78, pp.619~630 (2011)
- Prentice A, "Diet, nutrition and the prevention of osteoporosis", Public Health Nutr, 7, pp.227~243 (2004)
- Bolland MJ, "Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial", BMJ, 336, pp.262~266 (2008)
- Bolland MJ, "Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis", BMJ, 341, pp.C3691~ (2010)
- Bolland MJ, "Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis", BMJ, 342, pp.d2040~ (2011)
- Peter R, "Severe hypocalcaemia after being given intravenous bisphosphonate", BMJ, 328, pp.335~336 (2004)
- Whitaker M, "Bisphosphonates for osteoporosis-where do we go from here?", N Engl J Med, 366, pp.2048~2051 (2012)
- Black DM, "Continuing bisphosphonate treatment for osteoporosis-for whom and for how long?", N Engl J Med, 366, pp.2051~2053 (2012)
- Gallagher JC, "Primer on the metabolic bone diseases and disorders of mineral metabolism" (2013), Wiley-Blackwell
- Ross AC, "The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know", J Clin Endocrinol Metab, 96, pp.53~58 (2011)
- Holick MF, "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 96, pp.1911~1930 (2011)
- Need AG, "Vitamin D metabolites and calcium absorption in severe vitamin D deficiency", J Bone Miner Res, 23, pp.1859~1863 (2008)
- Sai AJ, "Relationship between vitamin D, parathyroid hormone, and bone health", J Clin Endocrinol Metab, 96, pp.E436~446 (2011)
- Sahota O, "The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis", Bone, 35, pp.312~319 (2004)
- Bauer DC, "The calcium supplement controversy: now what?", J Bone Miner Res, 29, pp.531~533 (2014)
- Favus MJ, "Primer on the metabolic bone diseases and disorders of mineral metabolism", pp.173~179 (2013), Wiley-Blackwell
- Rush DN, "Evaluation of calcium and vitamin D supplementation in bisphosphonate therapy", J Am Pharm Assoc (2003), 47, pp.725~728 (2007)
- Ringe JD, "Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence", Drugs Aging, 23, pp.569~578 (2006)
- Ian R Reid, "Should We Prescribe Calcium Supplements For Osteoporosis Prevention?", 대한골대사학회지, 21(1), pp.21~28 (2014), 대한골대사학회
- Sugerman DT, "JAMA patient page. Osteoporosis", JAMA, 311, pp.104~ (2014)
- Manson JE, "Calcium supplements: do they help or harm?", Menopause, 21, pp.106~108 (2014)